Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There ya go whatever is comforting, Heart over here resides with flower its oil and associated stocks. If not for KING KONG rulers of law passing congress who like incarceration for usage of plants that have grown freely all over the earth for millions of years.
Million person march on the capitol might change things as fifty million should show up.
Prohibition is a crime against humanity. Making money off prohibition should be a crime but congress makes laws and could give two damns.
The web is a gift at these prices am thinking revenue will increase as cbd oil and covid go hand in hand.
Wrong answer on use of dry powder. How much was in the keg? Used some of mine late last week on yours truly. Whats left is for double bottom party if can get close enough this week or next. If not thats cool have enough shares to take a good ride the other way seeing more daylight than darkness from here. Looked at your hexo the other day when ya mentioned it and passed out waking up back here.
If the VA contacted every member with this questionnaire before even more die of the covid there would be a connection. Disabled Vets love Gods plants. Ask all of us if care. They don't and won't. They would be Woke if they did. Gov officials sometimes say inject bleach. For once want someone in Gov to state use cannabis for covid. Definitely more rational.
Have a personal connection as just got over the Delta picked up on the 4th of Aug popping positive 6 days later, back into society the 18th. Feb and Mar my two Moderna shots. I use cannabis every day "am 65" smoking eating and or vaping. Knew had the covid cause could not smell flowers crushed up to roll with the smoke tasting like crapolla burning hot on the lungs. Ran a small fever two days. Homemade edibles and cbd oil did the trick. There is a huge cannabis covid connection thats not French.
The VA will never know about any connection. Belong to the VA as disabled vet they care less about anything thats plant based, has become a tremendous pusher of anything pills. My Government Thanks me and us on Veterans day but break out the cuffs if break out the medicine thats outlawed. Man Biden, Clinton, Obama, don't never thank a vet again thats the case.
Clinical Trial: Use of CBD Associated with Greater Emotional Wellness
São Paulo, Brazil: The daily administration of CBD is associated with lower levels of emotional exhaustion, anxiety, and depression, according to clinical trial data published in JAMA Psychiatry.
A team of investigators affiliated with the University of São Paulo in Brazil evaluated the safety and efficacy of CBD treatment in a cohort of 120 frontline health care professionals. Half of the study’s participants received 300mgs of CBD daily for a period of four weeks. Others did not receive the substance.
Those undergoing CBD treatment exhibited fewer signs of emotional exhaustion and burnout as compared to those subjects who did not. CBD consumption was also associated with less anxiety and depression. However, five of the subjects assigned to use CBD had to eventually drop out of the trial after suffering from serious adverse events, including elevated liver enzymes.
“This randomized clinical trial found that the efficacy and safety of daily treatment with CBD, 300 mg, for 4 weeks combined with standard care was superior to standard care alone for reducing the symptoms of emotional exhaustion, anxiety, and depression among frontline health care professionals working with patients with COVID-19,” authors concluded. “Cannabidiol may act as an effective agent for the reduction of burnout symptoms among a population with important mental health needs worldwide.”
Full text of the study, “Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: A Randomized clinical trial,” appears in JAMA Psychiatry.
https://norml.org/news/2021/08/19/clinical-trial-use-of-cbd-associated-with-greater-emotional-wellness?link_id=5&can_id=85778403017004b8f760acde3c2c3e8c&source=email-norml-news-of-the-week-8192021-2&email_referrer=email_1265024&email_subject=norml-news-of-the-week-8192021
"THC sector challenge."
“After 2.5 years, it has become increasingly more apparent that in the FDA’s own words, potential legislation might be appropriate to enable a framework for under which the FDA can regulate full spectrum hemp extracts as dietary supplements,” said Elsner. “During the second quarter of 2021, we put this thesis to test by formally submitting a new dietary ingredient notification to the FDA for our full spectrum hemp extract as they have been recommending. The FDA responded with an objection letter to our NDI notification. Their response substantially based on their drug preclusion provision reveals that legislation is required to enable the FDA to establish a regulatory oversight for full spectrum hemp extracts as dietary supplements. Both the House and the Senate have introduced bills that would recognize hemp CBD as a dietary supplement and we are encouraged by this progress.”
When asked about the specifics of the letter, Elsner went on to say, “I will start with we were disappointed and strongly disagreed with not just the conclusion that they advanced, but the reasoning for their conclusions, because their letter back to us contained a significant amount of factual inaccuracies. And so the first thing I would tell you to do is on our website in the IR section, we have posted our response to the FDA. And we laid out an excruciating detail why we think they need to create the record in terms of what we submitted and what they concluded.
Now, that said, they drew a conclusion based on two examples. One was, they can’t move forward with an NDI as a dietary supplement because CBD is precluded, because it’s already a drug. And as you know, six months prior to the hemp bill being signed into law in December 2018, a drug was approved that’s CBD isolate. The second reason why they objected to our NDI was that they expressed safety concerns. And I think that’s the part that we are looking for a correction on, because regarding safety, the conclusions drawn just don’t appear to be based on the data we provided in our NDI. So, that’s we are trying to get focused on. In terms of what does it mean, I think what you are getting to is, it is the industry has been caught in a little bit of a catch-22, because the FDA has not been clear about the process by which they want companies to go through to gain regulatory clarity. And Congress has been pointing to the FDA to take responsibility for this.
And so our decision was full transparency, to force the issue to see who has the next decision. And with the FDA objecting to our NDI, it becomes very clear that the regulatory process to get established has to start with Congress, legislative and the FDA to regulate the dietary supplement for CBD, and then FDA can regulate within. And so I am confident there is a way to do this. Over the last 18 months, we have met with the FDA, about eight to ten different times and our meetings were very constructive. I have got a great deal of respect for the FDA. But I think they are in a bit of a catch-22, because they have approved the drug. And they can’t seem to move away from that precedent. And so Congress has to act. And I think once Congress acts, the FDA can be very clear about the process. The process is scientific. It’s intense. There is a ton of data that we have got to do to submit for it. And I feel really good having gone through this knowing what they are looking for. But now we need Congress to act. And when that happens, I think the category will be able to submit NDIs and the whole thing will begin to open up.”
THC Challenge
Elsner was asked whether relying on Congress would be any better and she answered, “This is not just a CBD hemp industry challenge. This is a THC sector challenge, because we are going through with hemp extracts with naturally occurring CBD is exactly what the cannabis industry is going to have to do following us. And so this is not Congress, maybe or maybe not engaging on the hemp CBD industry. This is Congress looking at a category today, that is roughly $17 billion to $20 billion in total in the US across 11 states where cannabis is legal and CBD participates. And so some kind of resolution has to be landed for how both of these categories are regulated. And the FDA has to have clarity and perspective about how they want companies to produce safe products for consumers in a way that is holding manufacturers to a very high level of standard. And so we are doing this for ourselves, but doing this for our category. We are doing this in support of our consumers. But it’s the whole sector that is going to put the pressure for Congress to act and push the FDA to move forward. And we will continue to push both fronts.”
https://www.greenmarketreport.com/charlottes-web-addresses-fda-rejection/
Tested 2.92 as per your post might have got someone to sell. Myself missed buying those inexpensive shares.
How ya know GladysThong is around to greet?
Prohibition about over the Federal Gov cant agree with incarceration of Disabled Vets for much longer in states where illegal. But they do, Where are those pardons? No President has ever cared about Vets and cannabis.. yet support the military with like 80% the national GDP.
Yes and furthermore,,,,, Short interest relatively high. When volume explodes there they are.
Cannabis is the future the Stanley brothers know that. There will be fireworks to behold when that bells struck in spite of Biden and his cans of beer. Booker has it going on with the ear of the President.
Deadwood no more cannabis that is,,, like ya stated. "Cannabis is temporary "DEADWOOD." Sad but true."
Case in point Tilray. May be isolated incident had great earnings. lets see if more companies start to surprise smoking to that!
In 2017, Mikael Sodergren, a liver and pancreatic cancer surgeon at Imperial College healthcare NHS trust, was finding himself becoming increasingly interested in the potential role of medical cannabis in treating pain, especially the discomfort experienced by patients after complex operations.
“I hope that I do a lot of good, but unfortunately in the short term, I inflict a lot of pain with cancer surgery,” says Sodergren. “So we’re reliant on pretty nasty painkillers, such as high-strength intravenous opioids, which we’re trying to move away from. They slow patients down and they cause complications.”
Sodergren was far from alone. Over the past 15 years, an increasing number of scientists have become interested in the potential benefits of medical cannabis for treating all kinds of illness, from multiple sclerosis to anxiety, sleep disorders and post-traumatic stress disorder.
The reason is that phytocannabinoids – chemicals that occur naturally in the cannabis plant – bind to receptors on the body’s endocannabinoid system, a complex cell-signalling network stretching throughout the whole body, which is involved in neurological functions ranging from pain-sensing to regulating the sleep-wake cycle.
The phytocannabinoid that has received the most attention of all is CBD. This has become of interest to pain researchers such as Sodergren, because some studies have suggested it might be capable of desensitising pain neurons connected to the endocannabinoid system, while it has been shown repeatedly to have anti-inflammatory effects, which can help reduce seizures in those with childhood epilepsy.
However, medical cannabis is a highly complex and at times contentious field, because it is not just one drug. In total, there are more than 400 different phytocannabinoids in the cannabis plant and while some treatments consist solely of CBD, others utilise the whole plant extract, while the more controversial treatments blend varying concentrations of CBD and tetrahydrocannabinol (THC), the psychoactive element of cannabis, which elicits the “high” experienced by recreational users. While some studies have suggested that THC might be effective at enhancing the effects of CBD, it has also been linked with an increased risk of psychosis.
“There are several concerns that scientists and medical professionals have with medical cannabis,” says Susan Weiss, director of the Division of Extramural Research at the National Institute on Drug Abuse, in the United States. “While cannabis is purported to have many benefits, very few indications have rigorous evidence around both the risks and benefits for medical use. Most major safety concerns are related to THC products, but there are also some safety concerns around the use of CBD products. The main safety concerns involve the use of a smoked product, which can lead to a chronic cough and bronchitis, and risks for certain populations such as those with a family history of schizophrenia or psychosis.”
It has been estimated that up to 1.4 million people in the UK are using cannabis for medical purposes
The data on the safety and efficacy of medical cannabis has been fragmented as patients access these products in so many different ways. While laws were changed in November 2018, allowing medical cannabis to be legally prescribed in the UK for the first time, the National Institute for Health and Care Excellence (Nice) has only licensed three CBD-based treatments for use on the NHS. These are available only for three rare types of childhood epilepsy, the vomiting and nausea associated with chemotherapy and multiple sclerosis-related spasticity.
To try to get a fuller picture of how different forms of cannabis are potentially benefiting patients, private clinics around the globe have begun creating dedicated medical-cannabis registers. These are collating as much data as possible on the types of cannabis being used by different patient groups, on what has proved effective and on any potential safety issues. In the coming years, they hope that this could persuade Nice, and regulators around the world to improve access to medical cannabis for more conditions.
Data collection
In December 2019, Sodergren established the UK Medical Cannabis Registry, to follow patients who have been prescribed various medical cannabis products by clinicians at the private Sapphire Medical Clinics practice for a range of different ailments.
In May 2021, results were released for the first 129 patients. These showed significant improvements in anxiety, pain and sleep-quality measurements after one and three months. Intriguingly in the context of pain, the treatments appeared to be better tolerated than conventional opioids.
Similar registers are being run by the non-profit research organisation Drug Science, while the Cannabis Care clinic in Auckland, New Zealand, has been following 253 patients on CBD-based treatments. They also demonstrated improvements in quality of life for people suffering from chronic pain and social anxiety.
Sodergren is hopeful that the accumulation of such data could lead to medical cannabis being regarded as a mainstream method of treating different types of pain in coming years. “It’s coming,” he says. “I think in five to 10 years we’re going to have an NHS-licensed drug for pain. I think there are other conditions such as anxiety and insomnia for which the evidence is going to build quickly and we’ll have licensed medicines.”
Scientific consensus is that CBD-based medical cannabis will become more widely available as a treatment for epilepsy
However, others feel that in the absence of rigorously conducted randomised controlled trials, the evidence base remains sparse, especially for complex conditions such as anxiety. Because the UK Medical Cannabis Registry data covers a range of different forms of medical cannabis, some say that it does not help with the tricky question of working out the best formulation and dose to use for a particular disease.
“The main issue we have is that medical cannabis use is still very poorly defined,” says Marta Di Forti, a psychiatrist at King’s College London. “When you look at the data out there, you don’t just have medicinal cannabis under one umbrella, you have different substances, taken at different doses, and sometimes combined with other medications and sometimes on their own. Because of this, when I have patients who want to buy CBD over the counter and try it, my recommendation is that they start with the lowest recommended dose and monitor if they experience any adverse side-effects, because we still know so little.”
The scientific consensus is that, in the near future, CBD-based medical cannabis is likely to become more widely available as a treatment for different forms of epilepsy, because of its known anti-seizure effects. The CBD-based medication Epidyolex is already licensed by Nice to treat three rare childhood epilepsies and experts in the field predict that it will eventually become available for more common childhood epilepsies and even adult epilepsy as well.
“Because of the success of CBD in controlling seizures in children with these rare, life-threatening conditions, so they go from hundreds of seizures a day to becoming nearly seizure-free, lots of clinical trials are continuing into using CBD for other forms of epilepsy,” says Gary Stephens, a professor of pharmacology at the University of Reading, who was involved in the development of Epidyolex. “That research is very much ongoing at the moment, but the initial findings look good and I strongly suspect in the next few years that we will be giving CBD for a range of epilepsies. But we need to do big clinical trials to prove that it’s better than the placebo.”
Recreational lobbies
Some scientists are concerned about how the growing interest in medical cannabis has been linked to organisations aiming to open up parallel and lucrative recreational markets for the drug. Last year, an investigation by the British Medical Journal uncovered connections between organisations researching the use of medical cannabis, such as Drug Science and the Centre for Medicinal Cannabis, with companies lobbying for wider access to recreational cannabis in order to cash in on a great, green windfall.
The potential rewards are obvious. According to Prohibition Partners, a marketing consultancy with a stated mission to open up the international cannabis industry, the entire UK cannabis market could be worth $1.7bn by 2024, if recreational use is also legalised in the next three years.
But not everyone is comfortable with the recreational and medical cannabis industries being entwined. “Wherever there is a financial interest, and we don’t have enough information scientifically to counterbalance the push for this product, I become very worried as a clinician,” says Di Forti. “We’ve seen this in the past with tobacco, which was once advertised as a way to reduce anxiety. I don’t want to see history repeating itself.”
Cannabis researchers say that some of the safety concerns over medical cannabis have been overblown, as they are based on data from recreational users, who are often consuming higher and more unregulated doses of the drug. “Cannabis containing THC is still highly stigmatised unfortunately,” says Anne Schlag, head of research at Drug Science. “Some of the issues associated with recreational use are not always applicable to medical use.”
Sodergren is keen to distance the debate about whether recreational cannabis should be legalised with research into the medical applications.
“The recreational perspective is really unhelpful to the development of medical cannabis in the UK,” he says. “What the academic medical profession needs is five to 10 years to tease out the indications what it’s going to be useful for and to really understand where these medicines fit in our treatment of illnesses. Having this parallel debate about recreational cannabis just isn’t helpful to that process at all.”
For scientists such as Stephens, the way forward is to focus on medical cannabis products that do not contain THC, in order more clearly to separate the medicinal element of these treatments from the recreational side.
“The reason why scientists started studying CBD is because it’s non-THC, so we can avoid the stigma,” he says. “When people first started using medicinal cannabis in the US, there was a big backlash, particularly when it came to use in children. People would come out and say, ‘How can you get your kids stoned?’ Getting Epidiolyx, a CBD-based medicine, into the clinic has helped with that. We’re not giving them anything that gets them euphoric, we’re giving them something useful and now more research is going on into CBD for other kinds of illnesses.”
https://www.theguardian.com/society/2021/jul/24/is-medical-cannabis-really-a-magic-bullet
Politics the real driver...... case in point, Amazon.
There are some indications, however, that Amazon is interested in trying to convince other companies and Congress to support legalization. A number of advocacy and industry groups, including Drug Policy Alliance, the National Organization for the Reform of Marijuana Laws and Canopy Growth Inc., have reported meeting with Amazon officials in the past month to discuss federal marijuana policy.
Amazon said last month that its “public policy team will be actively supporting The Marijuana Opportunity Reinvestment and Expungement Act,” otherwise known as the MORE Act, which would decriminalize cannabis and provide for expungement of some non-violent cannabis offenses, had been a long time coming. The company had preliminary conversations about whether to get involved in the national conversation on CBD — a substance contained in the cannabis plant that was federally legalized in 2018 — and marijuana last year, according to a person with direct knowledge of the matter, but there were internal disagreements about whether the company should do so and what the optics would be.
https://www.politico.com/news/2021/07/20/amazon-legal-weed-500263
Small retail cbd investors like me are supporting the negative effects of shorting thats taken place this 1/4. Yesterday had the inkling to add more at 3.07 and glad for that bringing average now down into the 3's from 4's. Will be easy to recover into the green. Keep the faith all and buy on weakness. Longs win the game from this price point.
Clarence Thomas says federal laws against marijuana may no longer be necessary
Clarence Thomas, one of the Supreme Court's most conservative justices, said Monday that because of the hodgepodge of federal policies on marijuana, federal laws against its use or cultivation may no longer make sense.
"A prohibition on interstate use or cultivation of marijuana may no longer be necessary or proper to support the federal government's piecemeal approach," he wrote.
His views came as the court declined to hear the appeal of a Colorado medical marijuana dispensary that was denied federal tax breaks that other businesses are allowed.
Thomas said the Supreme Court's ruling in 2005 upholding federal laws making marijuana possession illegal may now be out of date.
"Federal policies of the past 16 years have greatly undermined its reasoning," he said. "The federal government's current approach is a half-in, half-out regime that simultaneously tolerates and forbids local use of marijuana.”
Thirty-six states now allow medical marijuana, and 18 also allow recreational use. But federal tax law does not allow marijuana businesses to deduct their business expenses.
"Under this rule, a business that is still in the red after it pays its workers and keeps the lights on might nonetheless owe substantial federal income tax," Thomas said.
The Department of Justice has instructed the nation's federal prosecutors not to pursue cases against marijuana businesses that follow state law. And since 2015, Congress has prohibited the Justice Department from spending federal money to prevent states from carrying out their own laws.
But the IRS continues to enforce its own rules against growers and dealers.
The federal government's "willingness to look the other way on marijuana is more episodic that coherent," Thomas said.
I want to move to Maine. Nixon can continue to eat 6 ft of dirt on chest while 100% of America's populace is held in check with Federal Prohibition. allowing States to literally screw with people making money off it. Like Maines Governor. Since Nixon every President has agreed loving INCARCERATION then they go home celebrate with alcohol and pop some pills like ya see on tv commercials nowadays.
The Maine House of Representatives on Thursday approved a bill to decriminalize possession of all currently illicit drugs, delivering a victory to reform advocates on the 50th anniversary of President Richard Nixon’s declaration of the war on drugs.
The Senate also began consideration of the legislation on Thursday, but has not yet taken a vote.
The proposal, LD 967, was approved in 77-62 vote in the House. It would make possession of controlled substances for personal use punishable by a $100 fine, without the threat of incarceration. That fine could also be waived if a person completes a substance misuse assessment within 45 days of being cited.
“We are continually trying to criminalize a symptom of a disease. It hasn’t worked. It won’t work,” Rep. Charlotte Warren (D), who serves as the House chair of the legislature’s Criminal Justice and Public Safety Committee, said before the vote. “We have tried criminalizing this disease for decades, and 11 Mainers a week are dying.”
Rep. Anne Perry (D), sponsor of the bill, said that incarcerating people who are suffering from addiction “only proves to them that they are as bad as they think they are” and perpetuates the cycle of substance misuse. “Law enforcement is not the gateway to treatment and recovery. It’s a gateway to isolation and suicide.”
The measure’s passage flies in the face of Gov. Janet Mills (D), whose administration opposes the reform, as does the state attorney general. Coupled with opposition from Republican legislators, the bill faces an uphill battle to final passage.
People that use cannabis don't get Alzheimer's I don't think. Can't name a one yet the FDA says I cannot have my plant given to me by God. Yet churn out shady crap to make a buck off peoples lives,.........
In approving the first new Alzheimer's drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.
The Biogen Inc drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the lethal mind-wasting disease.
The FDA has granted so-called "accelerated approval" in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market.
Thanks man, nothing to do with us board lurkers. I feel like been on a boat rocking port and starboard with every deep list to port buying more. Feels as though currently the seas have started to lay down.
Volumes reveal all. One day a storm of volume will commence blowing us back onto a true starboard heading that selling into strength won't even stop. Talk about being in the money.
Ah,,,, smiling faces lie when don't tell the truth sort of thing?
What will ya do when happens? As,,,,, "can't wait for earnings."
19.33% of Float Held by Institutions. Number increasing every 1/4. Looking good.
What does YQU stand for?
This board sure has changed makeup. No longer fun visiting.
U.S. HEMP AUTHORITY ANNOUNCES IT WILL NOT CERTIFY “HEMP” PRODUCTS THAT ARE MARKETED FOR INTOXICATION
Board of Directors Approves Plan to Reject Certification of Delta-8 THC and other Products that Exceed Intoxicating Levels
The U.S. Hemp Authority®, the hemp industry’s initiative to provide high standards, best practices, and self-regulation, announced today that its nationally recognized certification program will not allow the participation of products that are sold under the guise of the hemp name, but that are marketed for their intoxicating effect. This certification prohibition will apply to products such as delta-8 THC that feature a total tetrahydrocannabinol concentration of more than 0.3 percent on a dry-weight basis.
The U.S. Hemp Authority’s Certification Program® was established to provide consumers and retailers confidence in hemp products. With the FDA waiting on plans to regulate CBD products, the industry has stepped forward to provide self-regulation to ensure there are products people can trust. With literally thousands of unregulated products on the marketplace, some improperly advertising themselves for intoxication or making unfounded medical claims, the U.S. Hemp Authority’s Certification Program® is especially needed to educate consumers.
“Recent press reports about the proliferation of potentially unsafe, intoxicating products calling themselves hemp have concerned consumers, retailers, law enforcement and policymakers,” stated Dr. Marielle Weintraub, President of the U.S. Hemp Authority. “We felt it was necessary to take a strong stand against these products so that people will know that the U.S. Hemp Authority® seal designates products that are truly hemp and that meet our rigorous standards.”
The U.S. Hemp Authority® recently released Version 3.0 of its Certification Standard, building on three years of stakeholder-involved improvements. For more information on the organization or certification program, go to www.ushempauthority.org.
U.S. Hemp Authority® Certification. As the exclusive certifying body for the U.S. Hemp Authority® Certification program, FoodChain ID provides the highest level of service throughout the certification process. Please visit https://www.foodchainid.com/usha/ for more information.
Is all about revenue which is increasing in a ever hostile environment, Well done. Am expecting much much much better results once prohibition is over. Institutions will back up pickup trucks for shares with Stanley brothers merger.
Nice! Thanks for posting.
Thats work for a lot of nothing you missed the two tall green lines negating whats smart money anyhow? More green lines to follow stimulus money enhanced.
Stand by to stand by for lift off or aint got no gas. Which is it? Institutions going to sell or buy more? You talking to them here? Or people like me..........
Am not worried about any of this I say I say I say. Trust the new admin in charge of America to follow Canada, Israel, Mexico, Portugal and many other countries lead. Heck North Korea never outlawed cannabis ever. This here is our turn this year to do the same prohibition over with.
CWEB has brilliant people that will benefit from this. Legalization will do a Reagonomic trickle on down to shareholders. Would not be surpised to find out a year from now covid 19 and prohibition are whipped
providing double whammies to revenue.
Got that right. America will be looking real dumb playing "monkey" in the middle for too long somethings going to give in a big way. I want as many shares as possible before that happens to be like a fat rat living in a cheese factory no traps.
Charlotte's Web Holdings Inc. said Wednesday it has reached an agreement that gives it the option to buy Stanley Brothers USA Holdings Inc., a privately held cannabis wellness company.
The five-year agreement give Charlotte's Web the option to acquire Stanley Brothers when the first of two events occurs: three years from the effective date of the deal, or with the federal legalization of cannabis in the U.S. The five-year term is extendable for an additional two years, the company said.
Charlotte's Web Chief Executive Deanie Elsner said that the deal gives her company a path to the U.S. cannabis wellness market in a potential partnership with Stanley.
As part of the deal, two Stanley Brothers founders, Joel Stanley and Jared Stanley, will resign their seats on the Charlotte's Web board of directors.
I knew the brothers would not watch another brother suffer. Bravo! Great Brotherly Love News!
Hold those reigns Reddit people jump on.
Meanwhile in Texas lock yer A up "they" say, but not for long Beto will be our next Governor.
Transition From Trump To Biden Impacts Federal Hemp And CBD Rules
President-elect Joe Biden’s pick to lead the Democratic National Committee (DNC) is a strong backer of marijuana legalization—the latest example of a nominee holding cannabis policy reform views that go further than the incoming president’s.
If confirmed by party leaders on Thursday, as is expected, former South Carolina Democratic Party Chair Jaime Harrison will be responsible for coordinating Democrats’ national political activities. To that end, a push from the chair to emphasize marijuana reform, which is overwhelmingly supported by Democratic voters, could be broadly influential.
Harrison made a 2020 run for a Senate seat held by outgoing Judiciary Committee Chairman Lindsey Graham (R-SC) but didn’t prevail. During his campaign, he stressed the need to legalize marijuana as a means to promote racial justice.
“I think we should legalize, regulate and tax marijuana like we do alcohol and tobacco,” he said in July. “There is simply no medical reason to lock people up over this issue. In essence, this is about common sense.”
https://www.marijuanamoment.net/biden-taps-marijuana-legalization-supporter-to-lead-democratic-national-committee/
How do you know someone else mind? If people could do that the world would truly be maddening.
A great week its been!
Bloods thicker than mud. Stanley brothers are changing the world.
If that is how the case turns out,,,,,,,, All brothers are together even though separated, one won't let another brother "suffer" integrating all companies into one.
Yippie Yi O Ki A! Lets see the Web go like were on Yippee beans this year!
In July, Senator-elect Jon Ossoff told CNBC: “I won’t just push for decriminalization; I’ll push for nationwide legalization of cannabis. The prohibition of this substance is irrational. It’s hugely expensive. It has a terrible human toll. The fact that there are people doing time for nonviolent marijuana-related offenses while others are getting rich in the cannabis industry is a grave injustice. I’ll fight for outright cannabis legalization, an end to incarceration for nonviolent drug offenses and expungement of records for nonviolent cannabis offenses.”
As a Pastor, Senator-elect Raphael Warnock discussed ending the drug war and repealing marijuana criminalization on multiple occasions. Specifically, he said: “Marijuana is seen as an illegal substance. It’s a terrible irony and we feel … that right now in America there are some folks who are becoming billionaires for selling the same stuff that’s got our children locked up all across America. Where is the justice? It’s not enough to decriminalize marijuana. Somebody’s gotta open up the jails and let our children go.”
Jan. 11, 2021 at 7:00 a.m. CST
https://www.washingtonpost.com/politics/2021/01/11/biden-war-on-drugs/
President-elect Joe Biden built part of his political career on being known as a fighter in the “war on drugs,” supporting legislation as a senator that set harsh penalties for some drug offenses.
But as president, Biden could potentially oversee broad changes in federal drug policy, including how the government and law enforcement agencies view drug addiction and treatment and classify the use of marijuana.
Biden will take office at a time when the nation’s attitudes about drugs, particularly the legalization or decriminalization of marijuana, appear to be one area where there is relative, and growing, bipartisan unity.
Oregon decriminalizes possession of hard drugs as four other states legalize recreational marijuana
In an election that was otherwise defined by stark political differences, voters in both red states and blue states — Arizona, Montana, New Jersey and South Dakota — supported ballot initiatives to legalize the personal use of marijuana, while Mississippi voters legalized it for medicinal use. Along with earlier action by state legislatures or voters, 15 states have legalized marijuana, while 36 others have approved some form of medicinal marijuana use, according to the National Conference of State Legislatures.
But marijuana remains illegal under federal law, leaving users and suppliers vulnerable to prosecution even in places where the drug is otherwise legally sold and used. The nation’s growing cannabis industry also faces hurdles in transporting its products across state lines and accessing the country’s federally regulated banking system.
During his primary campaign, Biden was one of the few Democratic candidates who did not support federal legalization of marijuana for recreational use, citing concerns that it could be a “gateway drug.” But during the general-election campaign, he softened his stance, saying that the drug should be decriminalized and that individual states should decide whether to legalize it for recreational use.
As the general-election campaign progressed, Kamala D. Harris, Biden’s running mate and a former prosecutor, also advocated for the decriminalization of marijuana despite past opposition to legalizing it. During the October vice-presidential debate, Harris said a Biden-Harris administration “will decriminalize marijuana, and we will expunge the records of those who have been convicted of marijuana” crimes.
As Biden zeroes in on attorney general pick, some worry one contender is too moderate on criminal justice issues
Marijuana advocates are gearing up to make sure Biden sticks to his campaign pledge, which they note that strong majorities of Democratic voters support, according to recent polls.
Last month, for the first time, the Democratic-controlled House voted — 228 to 164 — to decriminalize marijuana and remove it from the federal schedule of controlled substances. The Republican-controlled Senate did not take up the measure, and many advocates are skeptical of its chances there, even though Democrats narrowly won control of the chamber after two runoff elections in Georgia last week.
But advocates say Biden can still push toward decriminalization, even without a vote from Congress.
Under its current classification, which dates to a decision made under President Richard Nixon in 1970, marijuana is classified as a Schedule I narcotic for having “no currently accepted medical use and a high potential for abuse.” The remaining schedules of narcotics, II through V, are ranked by their potential for abuse and perceived level of danger, and the classifications help guide federal enforcement and regulations for controlled substances, including prescription medication.
Maritza Perez, director of national affairs for the pro-reform Drug Policy Alliance, said legal analysts for the movement think the Biden administration can unilaterally reschedule marijuana to a higher classification or even remove it from the list. Although she prefers congressional action, Perez said the administration could declassify marijuana through a process that would involve sign-off from the incoming attorney general as well as the secretary of the Department of Health and Human Services.
Biden has nominated California Attorney General Xavier Becerra, who has defended his state’s legalization of marijuana, as his secretary of Health and Human Services.
“The attorney general would have to work hand-in-hand with the HHS secretary, but we think this is certainly something within the administration's power, which is why the marijuana advocates have been pushing for him to appoint a pro-marijuana AG,” Perez said.
But Sam Kamin, a law professor at the Sturm College of Law at the University of Denver and a leading expert on marijuana laws, is skeptical that Biden will aggressively pursue the unilateral rescheduling or de-scheduling of marijuana. De-scheduling the drug could upend international drug control treaties, while rescheduling it could undercut state medical marijuana laws, he said.
“They can begin the rescheduling process, but whether they can de-schedule without stepping on other rules and regulations is more complicated,” Kamin said. “Treating marijuana like a Schedule II or III drug would create serious tensions with a lot of states. … If it was scheduled the same way Vicodin is scheduled, you could not get it over-the-counter as you can in many states. You would need a prescription from a medical doctor.”
Even if Biden decides to largely steer clear of the marijuana debate, advocates for reforming the nation’s drug laws still think his administration will usher in a new period of compassion when it comes to addiction.
To combat the opioid crisis, Biden has promised to spend an additional $125 billion over 10 years on drug treatment and prevention programs, while also supporting some controversial local initiatives such as needle exchanges.
Perez is optimistic that the Biden administration, unlike President Trump’s, will take a hands-off approach when it comes to proposals by some cities to open safe-injection sites, where people can use illegal drugs in safe, monitored environments.
Last year, the Trump administration sued to try to stop Philadelphia from opening a so-called safe injection site. But Perez noted in July that Becerra, as California attorney general, joined a multistate amicus brief in support of Philadelphia.
““Safe injection sites … are an innovative tool to combat the opioid epidemic and drug dependency while reducing overdose death and transmission of diseases,” Becerra said at the time.
Amy B Wang contributed to this report.
Updated January 11, 2021